Marketed in 56 countries across Europe, the Americas, the Middle East, and the Asia-Pacific region, Neurontin is a globally distributed brand of gabapentin, classified as an anticonvulsant with analgesic properties. It is one of the more internationally recognised names in this therapeutic area, and travellers, expatriates, and migrating patients regularly need to identify how the same molecule appears in a new country.
Neurontin is prescribed within two broad therapeutic areas. The first is epilepsy, where gabapentin is used in the management of partial seizures. The second is neuropathic pain, including neuralgia and pain associated with diabetic neuropathies. The structured indication block further down this page lists the specific registered uses recognised by national regulators in each market where Neurontin is sold.
Because the brand has such a wide footprint, the same active ingredient circulates worldwide under several commercial names — Neurontin in many countries, and gabapentin generics in others. Markets where Neurontin is registered include Brazil, Canada, China, Egypt, and Finland, but prescription rules, packaging, and the availability of generic alternatives vary considerably from one regulator to another. A pharmacist in the destination country can confirm whether a locally stocked gabapentin product corresponds to what the patient has been taking at home.
Other medications in the broader anticonvulsant and neuropathic-pain categories also exist internationally under different active ingredients, although molecules within these categories are not interchangeable without medical guidance. For long-term therapies of this kind, continuity of treatment is a clinical question rather than a shelf-comparison one. Anyone taking Neurontin, or trying to identify a local equivalent while abroad, should keep that decision within the care of a qualified healthcare provider.
Neurontin is prescribed in two broad therapeutic areas: epilepsy, including the management of partial seizures, and neuropathic pain conditions such as neuralgia and pain associated with diabetic neuropathies. It belongs to the anticonvulsant category, with recognised analgesic use in nerve-related pain. The structured indication list below this introduction details each registered use as recognised by regulators in the markets where Neurontin is sold.
Neurontin contains gabapentin, classified as an anticonvulsant and used as an analgesic in neuropathic pain. Gabapentin is the same molecule whether it is dispensed under the Neurontin brand or as a generic — internationally, the same active ingredient circulates under multiple commercial names, particularly in markets where the original patent has expired and several manufacturers produce gabapentin products in parallel.
Neurontin carries marketing authorisation in 56 countries, spanning Europe, the Americas, the Middle East, Asia, and Oceania. Examples include Australia, Brazil, China, Egypt, Canada, Denmark, and Argentina. If your country is not represented in the list shown on this page, a local pharmacist can usually confirm whether gabapentin is available in that market, either under the Neurontin brand or as a generic equivalent.
Gabapentin is sold under several brand names worldwide and is widely available as a generic in markets where the original patent has expired. Other medications within the broader anticonvulsant and neuropathic-pain categories also exist under different active ingredients, although molecules within these classes are not freely interchangeable. To identify a local gabapentin-containing product, search the active ingredient on Pill2Trip or ask a pharmacist in your country.
Yes. Neurontin is a prescription medication, and treatment for epilepsy or neuropathic pain is typically calibrated to the individual patient over time. This matters particularly for travellers and people relocating between countries, where prescription rules, available formulations, and generic options can differ across regulatory systems. Any decision to start, continue, switch, or discontinue gabapentin therapy should be made together with a qualified healthcare provider familiar with the patient.
